FDA approves Corcept's relacorilant combination for platinum-resistant ovarian cancer
Go back to FDA approves Corcept's relacorilant combination for platinum-resistant ovarian cancer| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 84.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $84.75 | 52 Week High | $10.00 | |||
| Open | $84.75 | 52 Week Low | $3.22 | |||
| Day High | $84.75 | P/E | N/A | |||
| Day Low | $84.75 | EPS | $-0.46 | |||
| Volume | 29 | |||||
